Related Experiment Video
Updated: Jun 16, 2026

A Retrograde Implantation Approach for Peritoneal Dialysis Catheter Placement in Mice
Published on: July 20, 2022
Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution
1Renal Division, Baxter Healthcare, McGaw Park, Illinois 60085, USA. cliff_holmes@baxter.com
Abstract:
Peritoneal dialysis (PD) is a well-established form of therapy for stage 5 chronic kidney disease requiring renal replacement therapy. D-Glucose has been used successfully for several decades as the osmotic agent employed in dialysis solutions to achieve adequate fluid removal. The absorption of 100-200 grams of glucose per day has been suggested as potentially increasing cardiometabolic risk, particularly in patients with diabetes. Supporting and undermining evidence for this hypothesis is reviewed, with a focus on the role of glucose absorption in changes in body composition, dyslipidemia, and glycemic control in diabetic PD patients. Clinical strategies to optimize fluid removal while minimizing the metabolic impact of glucose absorption are also discussed.
Related Concept Videos
Peritoneal Dialysis I: Introduction and Procedure
Peritoneal Dialysis III: Nursing Management
Dialysis
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Dialysis
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications
Chronic Kidney Disease III: Interprofessional Care
